New Delhi: The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert urging caution over the use of the commonly prescribed painkiller Meftal, used primarily by women to relieve menstrual cramps and arthritis-related discomfort. The alert warns of serious adverse reactions, including the potentially life-threatening DRESS syndrome.
Mefenamic acid, the key component of Meftal, is widely used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhoea (painful periods), mild to moderate pain, inflammation, fever, and dental pain. However, recent preliminary analysis from the Pharmacovigilance Programme of India (PvPI) has revealed worrying trends.
Multiple Organs at Risk
According to the IPC’s alert, initial data points to adverse reactions like eosinophilia and systemic symptoms linked to mefenamic acid. The report stresses that both healthcare providers and patients must closely monitor any signs of adverse drug reactions (ADRs) related to this medication.
Experts caution that excessive intake of Meftal can lead to DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)—a severe and delayed allergic reaction. The syndrome can affect multiple organs including the liver, kidneys, and blood system, and may prove fatal if not diagnosed early.
What is DRESS Syndrome?
DRESS syndrome affects roughly 10% of those who experience drug-induced allergies. Symptoms typically appear 2 to 8 weeks after starting the medication and may include fever, red rashes on the skin, swollen lymph nodes, blood irregularities, and organ inflammation.
The IPC has strongly advised consumers to consult medical professionals before taking painkillers, especially during menstruation, and to report any unusual symptoms promptly.
